Recent developments in targeting access to high cost medicines in Australia

Australia and New Zealand Health Policy

Volumn 2, Issue 1, 2005, Pages

  Lu, Christine Y ^a,b   Ritchie, Jan ^c   Williams, Kenneth M ^a,b   Day, Richard O ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Access to medicines; Drug reimbursement; Pharmaceutical benefits scheme; Tumour necrosis factor inhibitors

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; AUSTRALIA; CLINICAL PRACTICE; CONSULTATION; CONTROLLED STUDY; DECISION MAKING; DRUG COST; EXPERIMENTAL DESIGN; HEALTH CARE ACCESS; HEALTH CARE INDUSTRY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; PATIENT SELECTION; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; QUALITATIVE RESEARCH; RHEUMATIC DISEASE; SEMI STRUCTURED INTERVIEW;

EID: 33845201146     PISSN: 17438462     EISSN: None     Source Type: Journal    
DOI: 10.1186/1743-8462-2-28     Document Type: Article

References (23)

1. Organisation for Economic Co-operation and Development (OECD): OECD Health Data: Statistics and indicator for 30 countries 2005.
2. Commonwealth Department of Health and Aged Care: The Australian health care system: an outline. Canberra 2000.
3. Sansom L: The subsidy of pharmaceuticals in Australia: processes and challenges. Australian Health Review 2004, 28:194-205.
4. Henry D: Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals. Pharmacoeconomics 1992, 1:54-67.
5. Productivity Commission: International pharmaceutical price differences: research report Canberra: AusInfo; 2001.
6. Sansom L: The Australian National Medicinal Drug Policy. Journal of Quality Clinical Practice 1999, 19:31-35.
7. Australian Institute of Health and Welfare (AIHW): Health expenditure in Australia 2002-03. AIHW Cat No HWE 27 (Health and Welfare Expenditure Series No 20) Canberra: AIHW; 2004.
8. Symmons DP, Silman AJ: Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis & Rheumatism 2004, 50:1703-1706.
9. Fleischmann RM, Iqbal I, Stern RL: Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opinion on Drug Safety 2004, 3:391-403.
10. Lu CY, Williams K, Day R, March L, Sansom L, Bertouch J: Access to high cost drugs in Australia: Risk sharing scheme may set a new paradigm. BMJ 2004, 329:415-416.
11. Commonwealth Department of Health and Ageing: Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners (1 April 2005) [http://wwwl.health.gov.au/pbs/]
12. Vuorenkoski L, Toiviainen H, Hemminki E: Drug reimbursement in Finland - a case of explicit prioritising in special categories. Health Policy 2003, 66:169-177.
13. Singer PA, Martin DK, Giacomini M, Purdy L: Priority setting for new technologies in medicine: qualitative case study. BMJ 2000, 321:1316-1319.
14. Wirtz V, Cribb A, Barber N: Reimbursement decisions in health policy - extending our understanding of the elements of decision-making. Health Policy 2005, 73:330-338.
15. Australian Government, The National Health (Pharmaceutical Benefits) Regulations 1960 (made under The National Health Act 1953) [http://www.comlaw.gov.au/]
16. Medicare Australia [http://www.medicareaustralia.gov.au/]
17. Wiseman V, Mooney G, Berry G, Tang KC: Involving the general public in priority setting: experiences from Australia. Social Science & Medicine 2003, 56:1001-1012.
18. Cayton H: Patient and public involvement. Journal of Health Services Research & Policy 2004, 9:193-194.
19. Florin D, Dixon J: Public involvement in health care. BMJ 2004, 328:159-161.
20. Lu CY, Williams KM, March L, Bertouch JV, Day RO: Subsidised access to TNF-alpha inhibitors: is the rationale for exclusion of rheumatoid factor negative patients defensible? Medical Journal of Australia 2004, 181:457-458.
21. Mann EL: Subsidised access to TNF-alpha inhibitors: is the rationale for exclusion of rheumatoid factor negative patients defensible? Medical Journal of Australia 2005, 182:47-48.
22. Commonwealth Department of Health and Ageing: Recommendations made by the Pharmaceutical Benefits Advisory Committee in March 2005 [http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ pbacrec-pbacrecmar05]
23. Weekes LM, Mackson JM, Fitzgerald M, Phillips SR: National prescribing service: creating an implementation arm for national medicines policy. British Journal of Clinical Pharmacolology 2005, 59:113-116.